详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Oncogenic lncRNA BBOX1-AS1 promotes PHF8-mediated autophagy and elicits sorafenib resistance in hepatocellular carcinoma

83| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Department of Hepatobiliary Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, China [2]Hepatic Surgery Center, Tongji Medical College, TongjiHospital, Huazhong University of Science and Technology, Wuhan, China [3]Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Wuhan, China [4]The FirstAffiliated Hospital, College of Medicine, Shihezi University, Shihezi, Xinjiang, China [5]NHC Key Laboratory of Prevention and Treatment of Central Asia HighIncidence Diseases, Beijing, China

出处：

DOI：

ISSN：

摘要：

Some long non-coding RNAs (lncRNAs) have been documented to be involved in cancer progression and anticancer drug resistance in hepatocellular carcinoma (HCC). Thus, approaches designed to target these genes may facilitate the development of promising strategies for treating HCC. Previously, we showed that lncRNA BBOX1-AS1 was highly expressed and played an oncogenic role in HCC. However, the potential functions and mechanisms through which BBOX1-AS1 regulates HCC progression and drug resistance remain unclear. This study revealed that BBOX1-AS1 could promote tumor progression, autophagy, and drug resistance by upregulating PHF8 in HCC cells. Mechanistically, BBOX1-AS1 enhanced the stability of PHF8 mRNA by targeting the PHF8 inhibitor miR-361-3p to regulate tumor progression and autophagy in HCC. The functional rescue experiments showed that PHF8 acted as a key factor in regulating the biological effects induced by BBOX1-AS1 and miR-361-3p in HCC, indicating that BBOX1-AS1 promotes tumor progression and sorafenib resistance by regulating miR-361-3p/PHF8. Finally, mouse tumor models and patient-derived organoid models were established to further confirm these findings. Taken together, the results demonstrate that BBOX1-AS1 promotes HCC progression and sorafenib resistance via the miR-361-3p/PHF8 axis.© 2022 The Authors.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 2 区医学

小类 | 2 区医学：研究与实验 3 区肿瘤学

最新[2025]版：

大类 | 2 区医学

小类 | 3 区医学：研究与实验 3 区肿瘤学

JCR分区：

出版当年[2021]版：

Q2 MEDICINE, RESEARCH & EXPERIMENTAL Q2 ONCOLOGY

最新[2023]版：

Q1 MEDICINE, RESEARCH & EXPERIMENTAL Q1 ONCOLOGY

影响因子： 5.3 最新[2023版] 5.2 最新五年平均 6.311 出版当年[2021版] 6.71 出版当年五年平均 7.2 出版前一年[2020版] 5.7 出版后一年[2022版]

第一作者：

第一作者单位： [1]Department of Hepatobiliary Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, China [2]Hepatic Surgery Center, Tongji Medical College, TongjiHospital, Huazhong University of Science and Technology, Wuhan, China [3]Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Wuhan, China

共同第一作者：

通讯作者：

通讯机构： [2]Hepatic Surgery Center, Tongji Medical College, TongjiHospital, Huazhong University of Science and Technology, Wuhan, China [3]Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Wuhan, China [*1]Hepatic Surgery Center, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：